Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2003 1
2008 1
2010 1
2011 1
2013 3
2015 1
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Acute promyelocytic leukemia current treatment algorithms.
Yilmaz M, Kantarjian H, Ravandi F. Yilmaz M, et al. Blood Cancer J. 2021 Jun 30;11(6):123. doi: 10.1038/s41408-021-00514-3. Blood Cancer J. 2021. PMID: 34193815 Free PMC article. Review.
APL, accounting for 10-15% of the newly diagnosed AML cases, results from a balanced translocation, t(15;17) (q22;q12-21), which leads to the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene. ...Later, t …
APL, accounting for 10-15% of the newly diagnosed AML cases, results from a balanced translocation, t(15;17) (q22;q12-21), which lead …
Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E, Farhana R, Kanimozhi E, Kumar PS, Kumaramanickavel G, Kumar CS. Suguna E, et al. Cardiovasc Hematol Disord Drug Targets. 2018;18(3):199-207. doi: 10.2174/1871529X18666180515130136. Cardiovasc Hematol Disord Drug Targets. 2018. PMID: 29766829 Review.
For better clinical management, cytogenetic finding in AML is necessary and in patients with normal karyotypes - molecular, epigenetic and proteomic biomarkers are very important in choosing which drugs to prescribe. Mutations of certain genes like NPM1, FLT3, CEBPA, RUNX1 …
For better clinical management, cytogenetic finding in AML is necessary and in patients with normal karyotypes - molecular, epigenetic and p …
Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
Lengfelder E, Hofmann WK, Nowak D. Lengfelder E, et al. Expert Rev Anticancer Ther. 2013 Sep;13(9):1035-43. doi: 10.1586/14737140.2013.833681. Expert Rev Anticancer Ther. 2013. PMID: 24053202 Review.
Acute promyelocytic leukemia (APL) is a rare form of acute myeloid leukemia. The specific translocation t(15;17), which results in the fusion gene PML-RARA is the diagnostic and pathomechanistic hallmark of APL. ...
Acute promyelocytic leukemia (APL) is a rare form of acute myeloid leukemia. The specific translocation t(15;17), which results in th …
Novel treatment of acute promyelocytic leukemia: As2O3, retinoic acid and retinoid pharmacology.
Zhu G. Zhu G. Curr Pharm Biotechnol. 2013;14(9):849-58. doi: 10.2174/1389201015666140113095812. Curr Pharm Biotechnol. 2013. PMID: 24433507 Review.
PML protein relocalizes into the wild-type nuclear body (PML-NB) configuration or/and wild-type RARa upregulated. ...Here, like v-erbA, PML/RARa is a (strong) transcriptional repressor of the RA receptor (RAR) complex, and PML/RARa fusion receptor g …
PML protein relocalizes into the wild-type nuclear body (PML-NB) configuration or/and wild-type RARa upregulated. ...Here, lik …
Retinoids and differentiation treatment: a strategy for treatment in cancer.
Cornic M, Agadir A, Degos L, Chomienne C. Cornic M, et al. Anticancer Res. 1994 Nov-Dec;14(6A):2339-46. Anticancer Res. 1994. PMID: 7825969 Review.
APL results from a malignant process that leads to the accumulation in the blood and in the bone marrow of myeloid precursor cells characterized by an abnormal behavior and a differentiation arrest. APL is characterized cytogenetically by a t(15;17) translocation which inv …
APL results from a malignant process that leads to the accumulation in the blood and in the bone marrow of myeloid precursor cells character …
Clinical features and treatment outcomes of pediatric acute promyelocytic leukemia in a Mexican pediatric hospital.
Dorantes-Acosta E, Medina-Sanson A, Jaimes-García Y, López-Martínez B. Dorantes-Acosta E, et al. Rev Invest Clin. 2013 Sep-Oct;65(5):392-8. Rev Invest Clin. 2013. PMID: 24687338
INTRODUCTION: Acute promyelocytic leukemia (APL) is a distinct type of acute myeloid leukemia (AML) characterized by chromosomal translocations involving the retinoid acid receptor alpha (RARA) gene on chromosome 17. ...In eight cases, the molecular biology-b …
INTRODUCTION: Acute promyelocytic leukemia (APL) is a distinct type of acute myeloid leukemia (AML) characterized by chromosomal transloc …
The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease.
Mistry AR, Pedersen EW, Solomon E, Grimwade D. Mistry AR, et al. Blood Rev. 2003 Jun;17(2):71-97. doi: 10.1016/s0268-960x(02)00075-9. Blood Rev. 2003. PMID: 12642121 Review.
Acute promyelocytic leukaemia (APL) is characterised by chromosomal rearrangements of 17q21, leading to fusion of the gene encoding retinoic acid receptor alpha (RARalpha) to a number of alternative partner genes (X), the most frequent of which are PML (>95%), PL …
Acute promyelocytic leukaemia (APL) is characterised by chromosomal rearrangements of 17q21, leading to fusion of the gene encoding r …
Utility and impact of early t(15;17) identification by Fluorescence In Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL).
Kolhe R, Mangaonkar A, Mansour J, Clemmons A, Shaw J, Dupont B, Walczak L, Mondal A, Rojiani A, Jillella A, Kota V. Kolhe R, et al. Int J Lab Hematol. 2015 Aug;37(4):515-20. doi: 10.1111/ijlh.12326. Epub 2015 Jan 14. Int J Lab Hematol. 2015. PMID: 25639817
The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h). ...
The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid r …
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Hasan SK, Lo-Coco F. Hasan SK, et al. Clin Lymphoma Myeloma Leuk. 2010 Oct;10 Suppl 3:S139-43. doi: 10.3816/CLML.2010.s.027. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21115433
Acute promyelocytic leukemia (APL) is characterized by a unique genetic aberration, the t(15;17) chromosome translocation. Translocation breakpoints are located within the promyelocytic leukemia (PML) locus on chromosome 15 and the retinoic acid receptor alph …
Acute promyelocytic leukemia (APL) is characterized by a unique genetic aberration, the t(15;17) chromosome translocation. …
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F. Hasan SK, et al. Blood. 2008 Oct 15;112(8):3383-90. doi: 10.1182/blood-2007-10-115600. Epub 2008 Jul 23. Blood. 2008. PMID: 18650449 Free PMC article.
Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17) translocation is a well-recognized complication of cancer treatment with agents targeting topoisomerase II. ...This study further supports the presence of preferential sites of DNA damage induced by …
Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17) translocation is a well-recognized complication of cancer t …
11 results